Skip to main content
In stock | Targeted Therapy (Antibody-Drug Conjugate)

Brentuximab Vedotin

Oncology Type Hematologic
Drug Class / Mechanism ADC
No Image
Description

Brentuximab Vedotin is classified as an ADC, sourced for use within our Targeted Therapy (Antibody-Drug Conjugate) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type Hematologic

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3